Literature DB >> 22883345

Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis.

Alexandre Belot1, Rolando Cimaz.   

Abstract

The pathogenesis of Systemic Lupus Erythematosus (SLE) is complex and remains poorly understood. Infectious triggers, genetic background, immunological abnormalities and environmental factors are all supposed to interact for the disease development. Familial SLE as well as early-onset juvenile SLE studies make it possible to identify monogenic causes of SLE. Identification of these rare inherited conditions is of great interest to understand both SLE pathogenesis and molecular human tolerance mechanisms. Complement deficiencies, genetic overproduction of interferon-α and apoptosis defects are the main situations that can lead to monogenic SLE.Here, we review the different genes involved in monogenic SLE and highlight their importance in SLE pathogenesis.

Entities:  

Year:  2012        PMID: 22883345      PMCID: PMC3489560          DOI: 10.1186/1546-0096-10-21

Source DB:  PubMed          Journal:  Pediatr Rheumatol Online J        ISSN: 1546-0096            Impact factor:   3.054


Systemic lupus erythematosus (SLE) is a complex disease: environmental factors (e.g. infections), immunological defects (responsible for tolerance breakdown), and genetic factors (mostly thought to be polygenic and associated to genetic polymorphism [1,2]) all play a role in its development. Rarely, lupus can be secondary to single gene mutations; we summarize recently discovered monogenic forms of lupus, and highlight the impact of these gene mutations on SLE pathogenesis.

Review

Complement defects: apoptotic cell and immune complexes clearance deficiency

Primary complement defects, especially in early components of the classical pathway, can lead to an increased susceptibility to SLE [3]. However, less than 1% of SLE cases are associated with complement deficiencies, and conversely complement deficiencies are not always associated to SLE [4]. C1q, C1s and C1r complete deficiencies are rare and associated with a high risk to develop pediatric SLE (estimated to 93% for C1q and 66% for C1s/r). C1q deficiency is associated with cutaneous rash in 90% of case and glomerulonopehritis in around 1/3 of cases [5]. Notably, the incidence of anti–double-stranded DNA antibodies "(anti-dsDNA)"is low. C4 deficiency is also strongly associated with SLE development (around 75%) [6-8] (Table 1). Homozygous C2 deficiency, which is the most frequent hereditary deficiency in classical pathway complement components (1/10,000 to 1/30,000 among caucasians), is associated with SLE in only 10 to 30% of the cases, suggesting that exogenous factors may be also involved. In all cases, early-onset disease and association with recurrent pyogenic or neisserial infections should evoke the diagnosis.
Table 1

Complement deficiencies

Complement deficiencyLocusInheritance patternClinical manifestationsInfection susceptibility
C1q
1p36.3-p34.1
AR
Nephritis, CNS involvement, photosensitivity
Encapsulated bacteria
C1r/C1s
12p13
AR
Nephritis
Encapsulated bacteria
C4
6p21.3
AR
Multiorgan involvement; glomerulonephritis
Encapsulated bacteria
C2
6p21.3
AR
Photosensitivity and articular involvement; mild or absent renal, neurological or pleuropericardial involvement
Pyogenic infections; encapsulated bacteria; Streptococcus pneumoniae sepsis and meningitis
C3
19q13
AR
Malar rash, photosensitivity, arthralgia and Raynaud’s phenomenon
Recurrent pyogenic infections
C5-C9: MACC5/9p34.1, C6-C7/5p13, C8A-C8B/1p32, C8G/9, C9/5p13ARMultiorgan involvementNeisserial infections
Complement deficiencies Complement deficiencies demonstrate the crucial role of complement in maintenance of tolerance (Figure 1). Early components of the classical pathway (especially C1q) help clearing apoptotic cells, thus decreasing the number of autoantigens [9]. Another role of complement is to process antibodies and eliminate circulating immune complexes, thus decreasing or avoiding vascular deposition. Interestingly, complement plays a role in T and B cell activation as well, and complement deficiency may upset the balance of lymphoid cell activation[10]. Finally, C1q has also been shown to inhibit in vitro interferon IFN-α production by plasmacytoid dendritic cells [11], and its deficiency can lead to defective suppression of IFN-α in response to immune complex-containing nucleoproteins [12].
Figure 1

Schematic views of monogenic SLE pathogenesis.

Schematic views of monogenic SLE pathogenesis.

Apoptosis defects

Apoptosis defects are thought to be involved in SLE pathogenesis as autoreactive B and/or T cells might survive death signals when they are ongoing central or peripheral tolerance. Nevertheless, to date there is no evidence that apoptosis-related gene defects involving B or T cell tolerance are directly involved in the pathogenesis of SLE. Autoimmune lymphoproliferative syndrome (ALPS) is the human counterpart of the lpr mouse, a widely explored model of murine lupus. Molecular mechanisms of ALPS are related to deficiencies of T cell apoptosis. Mutations in the Fas/FasL pathway underlie ALPS, which is characterized by lymphoproliferation in lymphoid organs associated with multiple autoimmunity [13]. One single case has been reported with classical features of SLE [14].

Interferon (IFN)-α hyperproduction

Genomic approaches have shown that human SLE leukocytes homogeneously express type I interferon (IFN)-induced transcripts [15]. In addition, large-scale genetic analyses have demonstrated that genes involved in IFN-α pathway such as IRF5IRF7 both expressed downstream of the endosomal TLR or STAT-4, transcriptional factor induced by Interferon type I were associated with SLE [16]. In the last years, studies on early-onset SLE and familial SLE led to the identification of new genes involved in IFN-α production (Table 2). This all started with the identification of the genes responsible for Aicardi-Goutieres syndrome (AGS) [17]. AGS is a rare genetic disorder occurring within the first few weeks of life that can mimic maternofetal infections, with an inflammatory encephalopathy. This autosomal recessive disease is associated with high IFN-α production [18]. Some children with AGS develop an early-onset form of SLE [19,20].
Table 2

Main features of mendelian SLE

Gene mutated/proteinChromosomeInheritanceClinical features
TREX1/TREX1
3p21
AD
Chilblain lupus, intracerebral calcifications
DNAse I/DNase I
16p13
AD
Systemic lupus, Sjögren syndrome,high levels of antinucleosomal antibodies
DNAse IL3/DNase1L3
3p14
AR
Early-onset SLE, antinuclear antibodies, anti-dsDNA, ANCA
AGS5/SAMHD1
20q11
AD
Chilblain lupus, intracerebral calcifications, mental retardation
ACP5/TRAP19p13ARGrowth retardation, spondyloenchondrodysplasia, SLE, Sjögren, vitiligo, myositis, Raynaud, ANA, anti-dsDNA

AD = autosomal dominant; AR = autosomal recessive.

Main features of mendelian SLE AD = autosomal dominant; AR = autosomal recessive. Nucleic acid are able to initiate an immune response, activating membrane receptors such as Toll-like receptors (TLR) or cytosolic sensors, involved in IFN-α production [21]. Defective clearance of self-derived nucleic acids can cause severe IFN-associated autoimmunity (Figure 1). One major mechanism by which these extracellular nucleic acids cause autoimmunity is through activation of TLR7 and TLR9 on autoreactive B cells [22,23]. Recently, it has been shown that TREX1 deficiency results in endogenous DNA accumulation and IFN-α production, independently from TLRs [24].

Rare cases of nuclease defects are responsible for monogenic lupus

DNAse type III, also called TREX1, is the main 3’-5’DNA exonuclease and has been shown to down-regulate IFN-stimulatory DNA response [24]. TREX1 knockout mouse develop an inflammatory cardiopathy [25]. Interestingly, TREX1 deficiency is responsible for intracellular DNA accumulation and TLR independent- IFN-α production[24]. TREX1 mutations in humans lead to Aicardi-Goutieres syndrome, chilblain lupus and represent the more common cause of monogenic lupus. Indeed, systematic TREX1 mutation screening in adult lupus patients revealed 0.5 to 2% heterozygosity, thus making TREX1 mutations the most frequent form of monogenic lupus [26,27].

Other gene involved in Aicardi Goutières syndrome

SAMHD1 is a protein, encoded by AGS5, that is upregulated in response to viral infections and may have a regulator role on immune system and cerebral vascular homeostasis [28,29]. One case of chillblain lupus in a 3-year-old boy with epilepsy was first diagnosed with a mutation in AGS5 gene [30]. Two additional cases have been reported with typical chillblain lupus, without central nervous system involvement [31]. AGS5 mutations can be associated with arthritis, chronic ulcers, mental retardation and microcephaly. Plasmatic IFN-α is increased, even though SAMHD1 deficiency has not yet been directly linked to IFN overproduction.

Spondyloenchondrodysplasia (SPENCD)

ACP5 is another gene, encoding tartrate-resistant acid phosphatase (TRAP), that has been associated to an immuno-osseous disease: the spondyloenchondrodysplasia (SPENCD). This syndrome is associated with platispondily, growth retardation and enchondromatosis. Various immunological findings have been reported including typical SLE with malar rash, lupus nephritis, antiphospholipid syndrome and anti-dsDNA [32]. Osseous anomalies can be subtle. TRAP is expressed in bone and in immune cells (mainly osteoclasts and dendritic cells) and is involved in bone resorption, even though its precise physiological role remains to be defined. Osteopontin (OPN, a substrate of TRAP) is a bone matrix protein involved in osteoclast adhesion and migration, and is dephosphorylated by TRAP [33,34]. In TRAP-deficient mice, OPN accumulates both around osteoclasts and in intracellular vacuoles, suggesting that TRAP is required for processing and/or degradation of OPN [16]. Interestingly, OPN accumulates in serum, urine and cells cultured from TRAP-deficient individuals and patients’ dendritic cells exhibit an altered cytokine profile, and are more potent than control cells in stimulating allogeneic T cell proliferation in mixed lymphocyte reactions [35]. OPN and IFN-α levels are both elevated in lupus patient’s sera and seems correlated [36]. In mouse, OPN is essential for IFN-α production, downstream of the Toll-like-receptor 9 in plasmacytoïd dendritic cells [37]. Taken together, TRAP deficiency may drive an inflammatory T cell response and promote IFN-α production in human.

DNASE1/DNASE1L3 mutation

DNAse type I is a widespread endonuclease that can be found in blood and urine. DNase1 deficiency in mouse induces the presence of ANA and the deposition of immune complexes in glomeruli [38]. Two unrelated cases of juvenile SLE were reported with a mutation in DNAse type 1 [39], and exhibited very high levels of antinucleosomal antibodies. This variant represent a very rare cause of lupus and further exploration in a large UK cohort of 170 SLE patients did not found any mutation [40]. Recently, a group from Saudi Arabia has identified DNASE1L3 as a new gene mutated in familial cases of juvenile SLE [41]. Mutated patients presented with association of anti-nuclear antibody, anti-dsDNA and ANCA. The link to SLE pathogenesis is unknown, but may be (as in TREX1 mutations) related to DNA accumulation, thus triggering IFN-α production.

Chronic granulomatous disease (CGD)

CGD is characterized by recurrent life-threatening infections by bacteria and fungi, due to severely impaired phagocyte intracellular destruction. CGD is caused by defects of NADPH (nicotinamide adenine dinucleotide phosphate) oxidase system, which is responsible for the generation of superoxide and other reactive oxygen species in phagocytic cells. The X-linked form, caused by mutations of the CYBB gene, accounts for more than 75% of the cases [42]. In the large U.S. series of 368 CGD patients, ten (2.7%) affected patients presented concomitantly discoid lupus (DLE) and 2 (0.5%) SLE. A large number of first-degree female relatives were also reported as having SLE or discoid lupus, while infection susceptibility was not increased. Cale et al. [43] investigated 19 mothers who carried the X-linked CGD allele for the presence of lupus manifestations. Remarkably, 12 of them presented photosensitivity, seven arthralgia, and eight had mouth ulcers. Anti-nuclear antibodies were positive in five, one had anti-dsDNA and another a lupus anticoagulant. The link between CYBB mutation and lupus may arise from the apoptosis defect of neutrophils in CGD patients, characterized by an impaired exposure of phosphatidyl serine on neutrophil membrane [44]. Moreover, in CGD neutrophil apoptosis is associated to diminished production of anti-inflammatory mediators [5]. Of note, neutrophils are now have been shown to be important in lupus pathogenesis, especially since mature SLE neutrophils are primed in vivo by type I IFN and die upon exposure to SLE-derived anti-ribonucleoprotein antibodies, releasing neutrophil extracellular traps (NETs) which contain DNA as well as large amounts of proteins that facilitate the uptake and recognition of mammalian DNA by plasmacytoid dendritic cells [45]. Indeed, SLE NETs activate pDCs to produce high levels of IFN-α in a DNA- and Toll-like receptor 9-dependent manner. Altogether, these data might suggest that CYBB and other CGD-related genes could be lupus-susceptibility genes.

Conclusions

Early onset lupus, familial lupus and syndromic lupus are rare situations that can lead to the identification of a unique gene responsible for the disease. Identification of this monogenic susceptibility to lupus can help to understand both lupus pathogenesis and tolerance breakdown in human immunology. To date, complement system deficiency, apoptosis defects and interferon overproduction have been confirmed as responsible for susceptibility to lupus. New genetic techniques such as exome sequencing could help to discover new genes and give insights in understanding SLE pathogenesis as well as molecular mechanisms of tolerance maintenance.

Abbreviations

AGS: Aicardi-Goutieres syndrome; CGD: Chronic granulomatous disease; IFN: Interferon; NETs: Neutrophil extracellular traps; SLE: Systemic lupus erythematosus; SPENCD: Spondyloenchondrodysplasia; TLR: Toll-like receptor.

Competing interests

The authors declare that they have no competing interest.

Authors’ contributions

AB and RC elaborated the draft and wrote the paper. Both authors read and approved the final manuscript.
  45 in total

1.  The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Authors:  Sandra Agik; Beverly S Franek; Akaash A Kumar; Marissa Kumabe; Tammy O Utset; Rachel A Mikolaitis; Meenakshi Jolly; Timothy B Niewold
Journal:  J Rheumatol       Date:  2011-11-01       Impact factor: 4.666

2.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

3.  Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus.

Authors:  Sulaiman M Al-Mayouf; Asma Sunker; Reem Abdwani; Safiya Al Abrawi; Fathiya Almurshedi; Nadia Alhashmi; Abdullah Al Sonbul; Wafaa Sewairi; Aliya Qari; Eiman Abdallah; Mohammed Al-Owain; Saleh Al Motywee; Hanan Al-Rayes; Mais Hashem; Hanif Khalak; Latifa Al-Jebali; Fowzan S Alkuraya
Journal:  Nat Genet       Date:  2011-10-23       Impact factor: 38.330

4.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

5.  IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.

Authors:  Timothy B Niewold; Jennifer A Kelly; Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Kenneth M Kaufman; Kenaz Thomas; Daniel Walker; Stan Kamp; Jacqueline M Frost; Andrew K Wong; Joan T Merrill; Marta E Alarcón-Riquelme; Mohammed Tikly; Rosalind Ramsey-Goldman; John D Reveille; Michelle A Petri; Jeffrey C Edberg; Robert P Kimberly; Graciela S Alarcón; Diane L Kamen; Gary S Gilkeson; Timothy J Vyse; Judith A James; Patrick M Gaffney; Kathy L Moser; Mary K Crow; John B Harley
Journal:  Ann Rheum Dis       Date:  2011-11-16       Impact factor: 19.103

6.  Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Authors:  Timothy B Niewold; Stephanie C Wu; Molly Smith; Gabrielle A Morgan; Lauren M Pachman
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

7.  Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke.

Authors:  Baozhong Xin; Stephen Jones; Erik G Puffenberger; Claas Hinze; Alicia Bright; Haiyan Tan; Aimin Zhou; Guiyun Wu; Jilda Vargus-Adams; Dimitris Agamanolis; Heng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

8.  Intrathecal synthesis of different alpha-interferons in patients with various neurological diseases.

Authors:  E Dussaix; P Lebon; G Ponsot; G Huault; M Tardieu
Journal:  Acta Neurol Scand       Date:  1985-06       Impact factor: 3.209

9.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Authors:  F Rieux-Laucat; F Le Deist; C Hivroz; I A Roberts; K M Debatin; A Fischer; J P de Villartay
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

10.  Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry.

Authors:  Nadera J Sweiss; Wei Zhang; Beverly S Franek; Silvia N Kariuki; David R Moller; Karen C Patterson; Peggy Bennett; Lakshmi R Girijala; Vaisak Nair; Robert P Baughman; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  15 in total

1.  Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Authors:  A Troldborg; S Thiel; L Jensen; S Hansen; M J Laska; B Deleuran; J C Jensenius; K Stengaard-Pedersen
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

2.  Buffalo liver transcriptome analysis suggests immune tolerance as its key adaptive mechanism during early postpartum negative energy balance.

Authors:  Sudhakar Singh; Naresh Golla; Davinder Sharma; Dheer Singh; Suneel Kumar Onteru
Journal:  Funct Integr Genomics       Date:  2019-05-09       Impact factor: 3.410

3.  Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.

Authors:  Cécile Picard; Jean-Christophe Lega; Bruno Ranchin; Pierre Cochat; Natalia Cabrera; Nicole Fabien; Alexandre Belot
Journal:  Pediatr Nephrol       Date:  2017-03-25       Impact factor: 3.714

4.  Paediatric rheumatic disease: Phenotype and prognosis of juvenile systemic lupus erythematosus.

Authors:  Rolando Cimaz
Journal:  Nat Rev Rheumatol       Date:  2016-06-16       Impact factor: 20.543

5.  [Pathogenesis of systemic lupus erythematosus].

Authors:  T Alexander; A Radbruch; F Hiepe
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

Review 6.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

Review 7.  Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.

Authors:  Savino Sciascia; Massimo Radin; Jinoos Yazdany; Maria Tektonidou; Irene Cecchi; Dario Roccatello; Maria Dall'Era
Journal:  Rheumatol Int       Date:  2017-03-03       Impact factor: 2.631

8.  Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.

Authors:  Rosanna Coppo; Licia Peruzzi; Alessandro Amore; Silvana Martino; Luca Vergano; Inna Lastauka; Arrigo Schieppati; Marina Noris; Pier Angelo Tovo; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2014-08-31       Impact factor: 3.714

Review 9.  Monogenic systemic lupus erythematosus: insights in pathophysiology.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-05-15       Impact factor: 2.631

10.  Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation.

Authors:  Alexandre Belot; Paul R Kasher; Eleanor W Trotter; Anne-Perrine Foray; Anne-Laure Debaud; Gillian I Rice; Marcin Szynkiewicz; Marie-Therese Zabot; Isabelle Rouvet; Sanjeev S Bhaskar; Sarah B Daly; Jonathan E Dickerson; Josephine Mayer; James O'Sullivan; Laurent Juillard; Jill E Urquhart; Shameem Fawdar; Anna A Marusiak; Natalie Stephenson; Bohdan Waszkowycz; Michael W Beresford; Leslie G Biesecker; Graeme C M Black; Céline René; Jean-François Eliaou; Nicole Fabien; Bruno Ranchin; Pierre Cochat; Patrick M Gaffney; Flore Rozenberg; Pierre Lebon; Christophe Malcus; Yanick J Crow; John Brognard; Nathalie Bonnefoy
Journal:  Arthritis Rheum       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.